Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2991 Gastroenteropancreatic (GEP) Neuroendocrine Neoplasia G3 (NEN G3) According to 2019 WHO Classification: A Comprehensive Clinicopathological Characterization Including Mismatch Repair (MMR) Proteins, PDL1 Expression and KRAS/BRAF Status

Introduction: In the 2019 WHO FOR NEN’S classification NETG3 have been distinguished from poorly differentiated neuroendocrine carcinoma (NEC). They are heterogeneous group concerning prognosis and treatment benefit.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ruiz G, Graselli J, Golubicki M, Rizzol M,

Keywords: G3 NEN, PD-L1, KRAS, BIOMARKERS,

#2843 Metastatic Risk in Pancreatic Neuroendocrine Tumors: A 16-Year Experience from Bogotá, Colombia. A Series Cases

Introduction: Pancreatic neuroendocrine tumors (pNET) are rare, have a wide range of phenotypes, increase incidence in recent years; which represents a challenge in diagnosis, treatment, and follow-up

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: González Devia D

Authors: Guzman Ruiz Y, Vera Torres A, López Panqueva R, Ardila Duarte G, González Devia D,

Keywords: Pancreatic neuroendocrine tumors, Pancreatic tumor, Prognosis, Neuroendocrine tumor, Gastroenteropancreatic tumor,

#1247 Recist versus Choi Criteria Response Assesment in Patients with Advanced Pancreatic Neuroendocrine Tumor (PNET) Treated with Sunitinib

Introduction: Classically, the response assessment to systemic treatment is based on RECIST. In PNET treated with antiangiogenic targeted therapy as sunitinib there is no good correlation between response rate and progression free survival (PFS). Choi criteria might be an alternative to RECIST to evaluate the effect of sunitinib in patients with advanced PNET

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Solis Hernandez P

Authors: Solis Hernandez M, Calvo-Temprano D, Jiménez-Fonseca P, Faez L, Ruiz A,

Keywords: sunitinib, PNET, Choi, RECIST,

#1011 Predictive Factors for Progression Free Survival (PFS) in Patients with Advanced Pancreatic Neuroendocrine Tumors (PNET) Treated with Sunitinib

Introduction: Sunitinib and everolimus were approved for treatment of progressive PNET based on phase III trial data. However, features that may influence outcome with these antitargets have not been well-established.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Jiménez-Fonseca P, Carmona A, Solis M, Faez L, Ruiz A,

Keywords: Sunitinib, pancreatic neuroendocrine tumor, prior treatment, predictive factor,

#971 Well-differentiated Pancreatic Neuroendocrine Tumors: Prognostic Significance of Pathological Parameters

Introduction: Well-differentiated (WD) pancreatic neuroendocrine tumors (pNET) are uncommon neoplasms and one challenge lies in predicting tumor behavior and managing these patients.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Pérez-Casanova L, Serrano T, Navas C, Ruiz N, Gomez A,

Keywords: pancreas, well-differentiated G2,

Abstract Submissions in 2023

Abstract submissions for 2023 will open in September 2022!

 

The 20th Annual ENETS Conference in 2023 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Conferences in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.